Bcl‐xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms-Reference-Cited by-同舟云学术

Bcl‐xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms

Published:2020-08-13 Issue:18 Volume:24 Page:10978-10986
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J Cell Mol Med

Author:

Petiti Jessica¹^ORCID,Lo Iacono Marco¹,Rosso Valentina¹,Andreani Giacomo¹,Jovanovski Aleksandar¹,Podestà Marina²,Lame Dorela¹,Gobbi Marco De¹,Fava Carmen¹,Saglio Giuseppe¹,Frassoni Francesco¹,Cilloni Daniela¹^ORCID

Affiliation:

1. Department of Clinical and Biological Sciences University of Turin Turin Italy

2. Department of Pediatric Hemato‐Oncology and Stem Cell and Cellular Therapy Laboratory Institute G. Gaslini Genova Italy

Funder

Associazione Italiana per la Ricerca sul Cancro

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcmm.15730

Reference38 articles.

1. The chronic myeloproliferative disorders: Clonality and clinical heterogeneity

2. A Gain-of-Function Mutation ofJAK2in Myeloproliferative Disorders

3. MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia

4. Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin

5. Leukemic Transformation in Myeloproliferative Neoplasms

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in JAK2 inhibition for the treatment of myelofibrosis;Expert Opinion on Pharmacotherapy;2024-06-12

2. Emerging drug profile: JAK inhibitors;Leukemia & Lymphoma;2024-05-13

3. New era for myelofibrosis treatment with novel agents beyond Janus kinase‐inhibitor monotherapy: Focus on clinical development of BCL‐X_L/BCL‐2 inhibition with navitoclax;Cancer;2023-08-16

4. Targeting Bcl-xL is a potential therapeutic strategy for extranodal NK/T cell lymphoma;iScience;2023-08

5. SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It;Clinical Lymphoma Myeloma and Leukemia;2023-05